Abstract
Alzheimer’s disease (AD) is supposed to stanch from inappropriate waving in the brain sections related to memory and perception. The incidence of AD in distressed person associated with an upsurge in the accumulation of amyloid plaque-rich senile plaques and neurofibrillary tangles in the brain. We hypothesize that a combination therapy provides a new treatment for AD. We propose that an anti-AD drug, NGA, a combination of NSAIDS, Galanthamine and ACS-40 may be useful in preventing the formation of amyloid plaques from β-amyloid. Being a widespread incurable disease, the treatment for Alzheimer’s has been at the forefront of the medical research work. We propose a novel drug-like NGA will allow for the effective control and treatment of the progression of AD by preventing acetylcholinesterase activity and reducing plaque formation that forms the distinctive symptom for the identification of the onset of AD. A combinatory use of NSAID with a natural neurotransmitter will allow for an efficient control of amyloid beta toxicity and will open doors for the treatment of a myriad of other neurodegenerative diseases.
Keywords: ACS-40, NSAIDS, Alzheimer disease, galanthamine, nivalis.
Current Drug Discovery Technologies
Title:NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease
Volume: 12 Issue: 4
Author(s): C. Subathra Devi, V. Mohanasrinivasan, C. George Priyadoss, Nikhil Arora, Bharti Singh, Neetu Mittal, Shubham Agarwal and Shwetank Saxena
Affiliation:
Keywords: ACS-40, NSAIDS, Alzheimer disease, galanthamine, nivalis.
Abstract: Alzheimer’s disease (AD) is supposed to stanch from inappropriate waving in the brain sections related to memory and perception. The incidence of AD in distressed person associated with an upsurge in the accumulation of amyloid plaque-rich senile plaques and neurofibrillary tangles in the brain. We hypothesize that a combination therapy provides a new treatment for AD. We propose that an anti-AD drug, NGA, a combination of NSAIDS, Galanthamine and ACS-40 may be useful in preventing the formation of amyloid plaques from β-amyloid. Being a widespread incurable disease, the treatment for Alzheimer’s has been at the forefront of the medical research work. We propose a novel drug-like NGA will allow for the effective control and treatment of the progression of AD by preventing acetylcholinesterase activity and reducing plaque formation that forms the distinctive symptom for the identification of the onset of AD. A combinatory use of NSAID with a natural neurotransmitter will allow for an efficient control of amyloid beta toxicity and will open doors for the treatment of a myriad of other neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Devi Subathra C., Mohanasrinivasan V., Priyadoss George C., Arora Nikhil, Singh Bharti, Mittal Neetu, Agarwal Shubham and Saxena Shwetank, NGA- A Novel Hypothetical Drug Model: Combinatorial Approach to Multifactorial Alzheimer's Disease, Current Drug Discovery Technologies 2015; 12 (4) . https://dx.doi.org/10.2174/1570163813666151117121210
DOI https://dx.doi.org/10.2174/1570163813666151117121210 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Functional Neuroimaging in Mild Cognitive Impairment
Current Medical Imaging Recent Developments in Deception Research
Current Psychiatry Reviews Winning a Won Game: Caffeine Panacea for Obesity Syndemic
Current Neuropharmacology Editorial: Advances in the Treatment of Neurodegenerative Diseases and Epilepsy
Current Pharmaceutical Design Role of Physical Exercise as Complementary Treatment for Epilepsy and other Brain Disorders
Current Pharmaceutical Design The Pleiotropic Effects of PPARs on Vascular Cells and Angiogenesis: Implications for Tissue Engineering
Current Stem Cell Research & Therapy Actigraphy for Assessing Light Effects on Sleep and Circadian Activity Rhythm in Alzheimer's Dementia: A Narrative Review
Current Alzheimer Research Full Kinetics and a Mechanistic Investigation of the Synthesis of Tetrahydrobenzo[ b]pyrans in the Presence of Sodium Acetate as a Catalyst by a One-pot Three-component Reaction
Letters in Organic Chemistry Recreational Drug Misuse and Stroke
Current Drug Abuse Reviews The Effects of Different Antioxidants on the Activity of Cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer’s Disease and Age-matched Normal Brains
Current Alzheimer Research Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer's Disease
Current Alzheimer Research Neovascular Age-Related Macular Degeneration and its Association with Alzheimer’s Disease
Current Aging Science Association of Platelet Activation with Vascular Cognitive Impairment: Implications in Dementia Development?
Current Vascular Pharmacology The Effect of Pharmacotherapy for Attention Deficit Hyperactivity Disorder on Risk of Seizures in Pediatric Patients as Assessed in an Insurance Claims Database
Current Drug Safety Preparation and Preliminary Evaluation of <sup>68</sup>Ga-Acridine: An Attempt to Study the Potential of Radiolabeled DNA Intercalator as a PET Radiotracer for Tumor Imaging
Anti-Cancer Agents in Medicinal Chemistry Molecular Dynamics Simulations of Intrinsically Disordered Proteins in Human Diseases
Current Computer-Aided Drug Design Memory Impairment is Associated with Serum Methylarginines in Older Adults
Current Alzheimer Research Resveratrol: New Avenues for a Natural Compound in Neuroprotection
Current Pharmaceutical Design Bioactivities of Iridoids
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Prevalence, Morbidities, and Treatments of Insomnia
CNS & Neurological Disorders - Drug Targets